All nirsevimab articles
-
NewsGuideline on respiratory infections in leukemia revised
People with leukemia have a weakened immune system due to the disease itself and treatment, which leads to an increased susceptibility to infections. In a revised guideline, experts summarize the findings of the past ten years on all viruses that cause respiratory infections.
-
NewsMonoclonal antibody nirsevimab provides strong protection against severe RSV in infants
Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis.
-
NewsNew tool may help prioritize high-risk infants for RSV immunization
On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious infections.
-
NewsNew tool helps identify babies at high risk for RSV
A new tool to identify infants most at risk for severe respiratory syncytial virus (RSV) illness could aid pediatricians in prioritizing children under 1 to receive a preventive medication before RSV season (October-April).
-
NewsFirst results in using new tools to tackle respiratory syncytial virus
Vaccines for pregnant women and use of monoclonal antibodies have been approved for use in the European Union to prevent respiratory syncytial virus (RSV) among young children. Are those tools working?